Cost-effectiveness analysis of genotype-guided treatment allocation in patients with alcohol use disorders using naltrexone or acamprosate, using a modeling approach

Similar Items

• Cost-effectiveness of extended release naltrexone to prevent relapse among criminal justice-involved individuals with a history of opioid use disorder
  by: Murphy, S.M
  Published: (2017)
• USER'S MANUAL TO ALLOCATE DRUG TREATMENT COSTS FOR ASSESSMENT AND MEASUREMENT
  Published: (2002)
• COST-EFFECTIVENESS OF ADJUVANT TREATMENT WITH ACAMPROSATE IN MAINTAINING ABSTINENCE IN ALCOHOL DEPENDENT PATIENTS
  by: RYCHLIK, R.
  Published: (2003)
• COST-EFFECTIVENESS OF DRUG ABUSE TREATMENT: RELEVANT ISSUES AND ALTERNATIVE LONGITUDINAL MODELING APPROACHES. EN: ECONOMIC COSTS, COST-EFFECTIVENESS, FINANCING, AND COMMUNITY-BASED DRUG TREATMENT
  by: HSER, Y.I
  Published: (1994)
• TREATMENT FOR DEPENDENT DRUG USE. A GUIDE FOR POLICYMAKERS
  by: STEVENS, A.
  Published: (2006)